What gets quieter as we get older?
We look at four age-related changes in the body, keeping the measured signal separate from the much bigger question of whether replacing it helps.
Juventa Peptides may earn money when readers become Promise patients.
The same word can hide different measurements.
“Lower” sounds simple until we ask lower where, compared with whom and measured how. Blood and muscle are different places. A concentration is different from a hormone released in pulses. An average across age groups is different from a measurement that follows the same person over time.
These observations do not establish a common rate of decline or an age at which treatment becomes necessary.
NAD+: a helper inside cells
NAD+ belongs to the coenzymes, helper molecules that assist enzymes; it is not a peptide. Enzymes are proteins that help chemical reactions happen; NAD+ takes part in energy chemistry and other cellular processes. The research describes age-associated decreases in tissue NAD+, with cell and mouse experiments investigating possible mechanisms.
A tissue measurement cannot by itself establish what an infusion does inside that tissue. Nor does evidence about an oral precursor, a starting material the body can convert, automatically describe NAD+ administered directly. The NAD+ guide separates those routes and questions.
MOTS-c: blood and muscle tell different stories
MOTS-c is a peptide whose genetic instructions come from mitochondria, the structures involved in cells’ energy supply. The body makes it, and researchers have measured it in blood and muscle. In a study of healthy aging men, circulating levels were lower in the older group while muscle levels were higher.
That detail matters. “MOTS-c falls with age” would leave out half the observation. The study did not give MOTS-c to people to see whether a symptom changed. It cannot establish a need for treatment, even if the natural signal deserves further research. Our MOTS-c page keeps the animal experiments separate from the human measurements.
Growth hormone: a pulse is not a reservoir
Growth hormone is released in bursts. GHRH, short for growth hormone-releasing hormone, is one of the signals that prompts the pituitary gland beneath the brain to release it. Research in younger and older men links aging with less nighttime growth-hormone output and suggests a contribution from reduced GHRH signaling.
Sermorelin copies a portion of GHRH. It is neither growth hormone itself nor a replacement for every change in the system. A smaller pulse does not establish an adult disease. The sermorelin guide explains why its former approval for children does not answer the adult aging question.
GHK: the measured peptide and the copper complex
GHK is a chain of three protein building blocks. GHK-Cu is GHK holding copper. A review of GHK and aging describes lower plasma GHK with age, while discussing cell and animal research. The measurement concerns GHK; the proposed preparation may be GHK-Cu. The distinction is part of the question, not a typographical nicety.
There is no established inference from less plasma GHK to a benefit from a GHK-Cu prescription. Our GHK-Cu reading considers the evidence without borrowing promises from cosmetic marketing.
An observation does not choose a prescription.
Promise Peptides provides a U.S. route for questions about NAD+, MOTS-c, sermorelin and GHK-Cu. A licensed provider reviews each request rather than treating an age bracket as a prescription. Compounded preparations are not FDA-approved, and the review may find the person ineligible.
We can acknowledge a biological pattern without accepting the sales argument sometimes attached to it. What remains unknown includes who, if anyone, gains a meaningful long-term result from the matching option, which risks accumulate and what comparison would answer those questions fairly. Age gives the question context. It does not supply the answer.
A question can be the next step.
Promise Peptides connects U.S. patients with licensed U.S. providers who examine every request and decide whether prescribing is appropriate. The review may find that a person does not qualify. Access differs with the patient’s state and the treatment. Licensed U.S. compounding pharmacies prepare prescriptions; compounded medicines prepared for these prescriptions are not FDA-approved.
Promise’s LegitScript certification does not give a medicine FDA approval.